title: Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats.
abstract: The effects of dopamine (DA) prodrugs (L-dopa and gludopa) and of a D1-selective agonist (fenoldopam) on glomerular hyperfiltration were studied in the early stage of diabetes in rats. Wistar rats received one injection of streptozotocin (STZ) and were treated 1 week later with L-dopa (2 x 10 mg/kg/day, s.c.), gludopa (2 x 3 or 2 x 10 mg/kg/day, s.c.), or fenoldopam (2 x 0.3 or 2 x 1 mg/kg/day, s.c.). Their renal functions were compared with those of untreated diabetic and nondiabetic control rats. STZ injection led to hyperglycemia that was kept moderate (20-25 mmol/L) by daily insulin therapy (2-4 U of NPH insulin). Within 2 weeks, glomerular hyperfiltration (polyfructosan clearance) developed in diabetic rats (30% increase vs. nondiabetic control). A rise in renal plasma flow (PAH clearance) was sometimes observed. One week of treatment with either L-dopa, gludopa, or fenoldopam normalized the glomerular filtration rate and decreased filtration fraction. These corrections occurred despite similar metabolic disturbance and kidney hypertrophy. Gludopa was less well tolerated by diabetic rats than L-dopa. Results with L-dopa showed that the normalization of glomerular hyperfiltration was linked to DA synthesis and stimulation of D1 receptors, since it was reversed by carbidopa, a dopa decarboxylase inhibitor, and by SCH 23390, a D1-selective antagonist. These data show that DA prodrugs and a D1 agonist can suppress diabetic glomerular hyperfiltration in the very early course of the disease in rats.
authors.affiliation: Institut de Pharmacologie, URA DO589 CNRS, Faculté de Médecine, Strasbourg, France.
authors.forename: M
authors.initials: M
authors.lastname: Barthelmebs
authors.forename: B
authors.initials: B
authors.lastname: Vailly
authors.forename: M
authors.initials: M
authors.lastname: Grima
authors.forename: J
authors.initials: J
authors.lastname: Velly
authors.forename: D
authors.initials: D
authors.lastname: Stephan
authors.forename: S
authors.initials: S
authors.lastname: Froehly
authors.forename: J L
authors.initials: JL
authors.lastname: Imbs
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D015259:Dopamine Agents / Q000627:therapeutic use*; D018818:Fenoldopam; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D011355:Prodrugs / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013311:Streptozocin
chemical_list: D001552:Benzazepines; D015259:Dopamine Agents; D011355:Prodrugs; D007980:Levodopa; D013311:Streptozocin; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D018818:Fenoldopam; D002230:Carbidopa